PDF(Pubmed)
Abstract：
In the recently published consensus statement on the treatment and management of type 1 diabetes issued by experts from the American (ADA) and European (EASD) diabetes societies, measurement of endogenous insulin secretion using fasting C-peptide is recommended as a diagnostic criterion. In contrast, our group recently suggested fasting C-peptide/glucose ratio (CGR) for the determination of endogenous insulin secretion. In addition, this ratio may turn out as a potential decision aid for pathophysiologically based differential therapy of diabetes. In this comment, the following points will be discussed: i) CGR as the basis of differential diagnosis of type 1 diabetes, ii) CGR as the basis of treatment decisions for or against insulin in diabetes, and iii) the ease of application of CGR in clinical practice. The use of CGR may complement the ADA/EASD recommendations and should provide a practical application in clinical practice.
摘要：
在美国（ADA）和欧洲（EASD）糖尿病协会的专家最近发表的关于1型糖尿病治疗和管理的共识声明中，建议使用空腹C肽测量内源性胰岛素分泌作为诊断标准。相比之下,我们小组最近建议空腹C肽/葡萄糖比（CGR）用于测定内源性胰岛素分泌。此外,这一比例可能成为糖尿病病理生理鉴别治疗的潜在决策辅助手段.在这篇评论中，将讨论以下几点：i)CGR作为1型糖尿病鉴别诊断的基础，ii）CGR作为糖尿病中胰岛素治疗决策的基础，和iii)CGR在临床实践中的应用简便性。CGR的使用可以补充ADA/EASD建议，并应在临床实践中提供实际应用。
